ReviewEndocrine connections2022
Menopause-associated risk of cardiovascular disease.
Review in Endocrine connections, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 94 citations in OpenAlex.
- Acute Effects of a High-Fat Meal Enriched with Pomegranate Seed Oil on Postprandial Lipemia and Endothelial Function in Postmenopausal Women: a Randomized Controlled Crossover Trial.The Journal of nutrition · 2026Trial
- Nicotinamide riboside and pterostilbene reduces frequency and severity of undesirable symptoms of the menopause transition: an open-label, pilot clinical trial.Frontiers in aging · 2026Trial
- Acute impact of inorganic nitrate supplementation after ischemia and during small muscle mass exercise in postmenopausal females: A pilot study.Physiological reports · 2024Trial
- Reduced protein carbonylation on hormone therapy is associated with improved fibrinolysis in postmenopausal women: the impact of PAI-1 and TAFI activity.Journal of thrombosis and thrombolysis · 2024Trial
- The Influence of Statin Therapy on Markers of Endothelial Dysfunction, Endocan and Endoglin, in Postmenopausal Women-A Prospective Study.Biomedicines · 2026Article
- Ellagic Acid Attenuates Oxidative Stress and Improves Cardiovascular Function Following Myocardial Infarction in Ovariectomized Rats.Journal of cellular and molecular medicine · 2026Article
- Analysis of inequality in cardiovascular mortality in Isfahan County: a retrospective registry-based study of social and demographic determinants.BMC public health · 2026Article
- Aging under scarcity and insecurity: chronic disease, functional limitation, and basic need material insecurity among older adults in Haiti.International journal for equity in health · 2026Article
- Sex-specific trajectories of blood pressure and pulse pressure across body mass index categories: a descriptive study based on 13-year health checkup data.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Article
- Pharmacological Management of ADHD in Women Across Perimenopause, Menopause and Post-Menopause.Drugs & aging · 2026Review
- The Potential Role of Dietary (Poly)phenols in Cardiometabolic Risk During Menopause: A Narrative Review.Nutrients · 2026Review
- Perceived cardiovascular disease risk among multi-ethnic postmenopausal women residing in Korea: a Q-methodological study.Women's health nursing (Seoul, Korea) · 2026Article
- Exploring the risk of venous thromboembolism in women with rheumatoid arthritis initiating menopausal hormone treatment in England.Rheumatology advances in practice · 2026Article
- Acupuncture for premature ovarian insufficiency: a systemic neuroendocrine perspective.Frontiers in endocrinology · 2026Review
- Thyroid feedback quantile-based index predicts 90-day all-cause mortality or readmission in hospitalized heart failure patients: a retrospective cohort study.Frontiers in endocrinology · 2026Article
- Human Cancers Derived from Either Genetic or Lifestyle Factors Are Initiated by Impaired Estrogen Signaling.Cancers · 2025Review
- Current evidence and research gaps in menopause management in women with type 1 diabetes mellitus: a narrative review.Endocrine connections · 2025Review
- Position Statement on Cardiometabolic Health Across the Woman's Life Course - 2025.Arquivos brasileiros de cardiologia · 2025Article
- Artificial Intelligence in Postmenopausal Health: From Risk Prediction to Holistic Care.Journal of clinical medicine · 2025Review
- Indigenous women's experiences, symptomology and understandings of menopause: a scoping review.BMC women's health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular disease (CVD) is of major concern in women entering menopause. The changing hormonal milieu predisposes them to increased CVD risk, due to a constellation of risk factors, such as visceral obesity, atherogenic dyslipidemia, dysregulation in glucose homeostasis, non-alcoholic fatty liver disease and arterial hypertension. However, an independent association of menopause per se with increased risk of CVD events has only been proven for early menopause (<45 years). Menopausal hormone therapy (MHT) ameliorates most of the CVD risk factors mentioned above. Transdermal estrogens are the preferable regimen, since they do not increase triglyceride concentrations and they are not associated with increased risk of venous thromboembolic events (VTE). Although administration of MHT should be considered on an individual basis, MHT may reduce CVD morbidity and mortality, if commenced during the early postmenopausal period (<60 years or within ten years since the last menstrual period). In women with premature ovarian insufficiency (POI), MHT should be administered at least until the average age of menopause (50-52 years). MHT is contraindicated in women with a history of VTE and is not currently recommended for the sole purpose of CVD prevention. The risk of breast cancer associated with MHT is generally low and is mainly conferred by the progestogen. Micronized progesterone and dydrogesterone are associated with lower risk compared to other progestogens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.